Launching a clinical trial globally requires careful planning around regional variations in start-up timelines. Different countries and regulatory agencies follow unique pathways for ethics approvals, regulatory submissions, and site activation. This article provides a practical, comparative guide on start-up timelines across major global regions to help trial professionals plan efficiently and avoid delays.

Why Start-Up Timelines Vary by Region:

Several factors influence the variability in start-up timelines worldwide:

• Different regulatory authority review periods
• Independent or centralized ethics committees
• Language translation requirements
• Contract negotiation timelines
• Local import/export or clinical trial insurance regulations

Understanding these nuances is crucial for a global study launch strategy and timeline forecasting.

North America: United States and Canada

United States: Start-up is relatively streamlined but hinges on FDA submissions and IRB reviews.

• IND Review by USFDA: 30 days post-submission (for non-exempt studies)
• IRB Approval: 4–6 weeks (central IRB is faster than local)
• Site Contracts & Budgeting: 2–4 weeks
• Total Start-Up Time: 60–90 days

Canada: Requires submission to Health Canada and REB (Research Ethics Board).

• Health Canada Review: ~30 days
• REB Review: 4–8 weeks
• Total Start-Up Time: 90–120 days

European Union (EU): Harmonized But Complex

Since the implementation of EU Clinical Trials Regulation (CTR), regulatory and ethics approvals are centralized, improving harmonization but still facing country-specific interpretation challenges.

• Regulatory Approval via CTIS: 60–90 days
• Ethics Review: Simultaneous or post-regulatory in some member states
• Contract & Budgeting: Adds 30–60 days depending on institution
• Total Start-Up Time: 120–180 days

Start-up timelines in countries like Germany, Spain, and Italy are longer due to layered review systems.

Asia-Pacific: Japan, China, and Australia

Japan (PMDA):

• Pre-submission consultation: Mandatory
• PMDA Approval: 90–180 days
• IRB Approval: ~60 days
• Total Start-Up Time: 180–240 days

China (NMPA/SFDA):

• Clinical Trial Application: 60–90 working days
• IRB Approval: 4–8 weeks
• Import License for IMP: Often a cause of delay
• Total Start-Up Time: 150–210 days

Australia (TGA):

• CTN Scheme: No formal TGA review, sponsor-notified
• Ethics Approval: 30–60 days (via HREC)
• Faster timelines with single-site ethics review
• Total Start-Up Time: 60–90 days

Latin America: Brazil and Mexico

Brazil (ANVISA):

• Ethics Review (CEP): 60–90 days
• Regulatory Review (CONEP/ANVISA): 90–180 days
• Total Start-Up Time: 150–240 days

Mexico:

• COFEPRIS Approval: 60–120 days
• IRB Review: 4–6 weeks
• Total Start-Up Time: 120–180 days

Middle East & Africa

Timelines in this region are often extended due to less digitized systems and limited ethics infrastructure.

• South Africa (SAHPRA): 90–120 days regulatory + 30–60 days ethics
• Saudi Arabia (SFDA): ~90–120 days total
• Typical Total Start-Up: 120–180+ days

Key Factors Impacting Timelines Globally:

• Single vs. multiple IRB/EC layers
• Regulatory review type (expedited vs full)
• Contract negotiation cycles
• Drug import/export requirements
• Availability of translation and submission support

Using SOPs for document readiness, like those on Pharma SOP templates, can significantly improve timelines.

Using Digital Tools to Accelerate Start-Up:

Modern clinical operations leverage platforms to streamline global start-up:

• eTMF systems for document management
• Study Start-Up platforms for tracking and escalation
• e-submission portals (CTIS, SUGAM, etc.)
• Centralized IRBs to reduce review time

Trial professionals must consider digital adaptation when operating across borders.

Best Practices for Managing Global Start-Up:

1. Map region-specific start-up timelines during feasibility
2. Build realistic Gantt charts with buffer time for each region
3. Engage local CROs or consultants with regulatory expertise
4. Standardize document templates across all sites
5. Track progress using dashboards and milestone alerts

Conclusion:

Clinical study start-up timelines vary widely across regions due to diverse regulatory landscapes and approval processes. Understanding these differences is key to realistic planning and risk mitigation. By aligning with local regulations, using centralized tools, and implementing SOP-driven workflows, study teams can accelerate activation timelines globally. For further guidance on document readiness and planning, platforms like Stability Studies can be valuable.